With reference to survival, polychemotherapy has been demonstrated to be statistically significantly more effective than monochemotherapy both in the adjuvant setting and in the metastatic situation. @entity0 demonstrates a dose-response relationship. Chemotherapy used in the conventional dose range should be given with adequate dose-intensity both in the adjuvant setting and for metastatic @entity1 . More dose-intensive combinations are almost always associated with a higher response rate in @entity1 ' metastatic disease, but these results have seldom been translated into an improved survival. For marrow requiring high-dose therapy, repeated phase II studies have demonstrated the possibility of a survival tail, which may be due to stage migration and @entity1 selection. At present we have at least 13 ongoing phase III studies in the adjuvant setting and at least 5 ongoing studies in the metastatic situation. These studies will give a definite answer on whether marrow-supported high-dose therapy is better than conventional therapy or if alternative approaches using tailored therapy will result in an equivalent outcome. In the future we must make better use of the present arsenal of drugs and examine the marked inter-individual variations in pharmacokinetic profiles for the drugs. We have to tailor the therapy to the @entity5 biological profile, in both the primary @entity5 and @entity3 with appreciation of heterogeneity and @entity5 progression. Based on these prerequisites, therapy can be either dose-intensive or in some instances continuous using lower doses.

Is there a role for intensive therapy in XXXX ?

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
